Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Shih-Feng, Anderson, Kenneth C., Tai, Yu-Tzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095983/
https://www.ncbi.nlm.nih.gov/pubmed/30147690
http://dx.doi.org/10.3389/fimmu.2018.01821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095983/
https://www.ncbi.nlm.nih.gov/pubmed/30147690
http://dx.doi.org/10.3389/fimmu.2018.01821

Ejemplares similares